(Q38630598)

4 September 2017

title

QSAR studies in the discovery of novel type-II diabetic therapies (English)

1 reference

4 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558613%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Mutasem O. Taha

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558613%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Areej Abuhammad

series ordinal

1

1 reference

4 September 2017

Mutasem O Taha

series ordinal

2

1 reference

4 September 2017

language of work or name

English

0 references

publication date

11 November 2015

1 reference

Expert Opinion on Drug Discovery

4 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558613%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558613%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558613%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

197-214

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26558613%20AND%20SRC:MED&resulttype=core&format=json

Global estimates of diabetes prevalence for 2013 and projections for 2035.

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Diabetic retinopathy and other ocular findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Earlier onset of complications in youth with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

21 January 2018

Oral Antidiabetic Agents

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

A review of the efficacy and safety of oral antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Addressing unmet medical needs in type 2 diabetes: a narrative review of drugs under development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Discovery of INT131: a selective PPARγ modulator that enhances insulin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

On various metrics used for validation of predictive QSAR models with applications in virtual screening and focused library design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Docking-based comparative intermolecular contacts analysis as new 3-D QSAR concept for validating docking studies and in silico screening: NMT and GP inhibitors as case studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Combining docking-based comparative intermolecular contacts analysis and k-nearest neighbor correlation for the discovery of new check point kinase 1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

On two novel parameters for validation of predictive QSAR models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Some case studies on application of "r(m)2" metrics for judging quality of quantitative structure-activity relationship predictions: emphasis on scaling of response data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Best Practices for QSAR Model Development, Validation, and Exploitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Data set modelability by QSAR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Structure−Activity Landscape Index: Identifying and Quantifying Activity Cliffs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

From activity cliffs to target-specific scoring models and pharmacophore hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Recent progress in understanding activity cliffs and their utility in medicinal chemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

How not to develop a quantitative structure-activity or structure-property relationship (QSAR/QSPR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

The inevitable QSAR renaissance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

QSAR modeling: where have you been? Where are you going to?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Modeling and informatics in designing anti-diabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Aldose reductase enzyme and its implication to major health problems of the 21(st) century.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Computation as a tool for glycogen phosphorylase inhibitor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

A new protocol for predicting novel GSK-3β ATP competitive inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

PLS and shape-based similarity analysis of maleimides--GSK-3 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Quantitative Structure-Activity Relationship Analysis and a Combined Ligand-Based/Structure-Based Virtual Screening Study for Glycogen Synthase Kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Validation of formylchromane derivatives as protein tyrosine phosphatase 1B inhibitors by pharmacophore modeling, atom-based 3D-QSAR and docking studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Sulphonamides as inhibitors of protein tyrosine phosphatase 1B: a three-dimensional quantitative structure-activity relationship study using self-organizing molecular field analysis approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Self-organizing molecular field analysis of 2,4-thiazolidinediones: A 3D-QSAR model for the development of human PTP1B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Studies on two types of PTP1B inhibitors for the treatment of type 2 diabetes: Hologram QSAR for OBA and BBB analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

The discovery of a novel and selective inhibitor of PTP1B over TCPTP: 3D QSAR pharmacophore modeling, virtual screening, synthesis, and biological evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Comparative molecular similarity indices analysis (CoMSIA) studies of 1,2-naphthoquinone derivatives as PTP1B inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Optimization of Gaussian Kernel Function in Support Vector Machine aided QSAR studies of C-aryl glucoside SGLT2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Additivity of molecular fields: CoMFA study on dual activators of PPARalpha and PPARgamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

'Sum of activities' as dependent parameter: a new CoMFA-based approach for the design of pan PPAR agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Quantitative structure-activity relationships for PPAR-gamma binding and gene transactivation of tyrosine-based agonists using multivariate statistics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

3D QSAR studies on peroxisome proliferator-activated receptor gamma agonists using CoMFA and CoMSIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Identification of novel peroxisome proliferator-activated receptor-gamma (PPARγ) agonists using molecular modeling method.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Role of physicochemical properties in the activation of peroxisome proliferator-activated receptor δ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Molecular features related to the binding mode of PPARδ agonists from QSAR and docking analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Development of a robust QSAR model to predict the affinity of pyrrolidine analogs for dipeptidyl peptidase IV (DPP- IV).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Activator or inhibitor? GSK-3 as a new drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

GSK-3 inhibition: achieving moderate efficacy with high selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Protein tyrosine phosphatases: molecular switches in metabolism and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

PTP1B inhibitors for type 2 diabetes treatment: a patent review (2011 - 2014).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Targeting the incretin system in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Early investigational drugs targeting PPAR-α for the treatment of metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

PPARγ signaling and metabolism: the good, the bad and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Novel directions for diabetes mellitus drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

Minireview: Challenges and opportunities in development of PPAR agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

CoMFA analysis of dual/multiple PPAR activators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046

QSAR Studies of PTP1B Inhibitors: Recent Advances and Perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2016.1118046